<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30181">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02007317</url>
  </required_header>
  <id_info>
    <org_study_id>OS-BCC-P2-01</org_study_id>
    <nct_id>NCT02007317</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Oshadi D and Oshadi R in Basal Cell Carcinoma Patients Prior to Tumor Excision a Phase 2 Study</brief_title>
  <official_title>A Single Center, Open Label Study for Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R in Patients With Basal Cell Carcinoma (BCC) Prior to Tumor Excision- a Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oshadi Drug Administration</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oshadi Drug Administration</source>
  <oversight_info>
    <authority>Israel: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is single-arm, none randomized, open label, two-dose-cohorts, single center
      clinical trial for evaluation of the safety and efficacy of Oshadi D and Oshadi R in
      patients with BCC. Patients will receive Oshadi D and Oshadi R for 60 -90 days until the
      planned surgical excision of the lesion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Adverse events and serious adverse events occurence</measure>
    <time_frame>treatment end (day 60 or 90)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The primary efficacy endpoint of this study is Overall Response Rate (ORR)</measure>
    <time_frame>treatment end (day 60 or 90)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>To estimate the duration of treatment to achieve response</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To estimate the duration of treatment needed to achieve response</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>BCC</condition>
  <arm_group>
    <arm_group_label>Oshadi D and Oshadi R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti tumor agents</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oshadi D &amp; Oshadi R</intervention_name>
    <description>Anti tumor agents</description>
    <arm_group_label>Oshadi D and Oshadi R</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 21 years old with tissue confirmed diagnosis of local BCC.

          -  Patient is candidate for surgical excision of the BCC in few months.

          -  BCC lesion ≥10mm in its longest diameter.

          -  Sexually active fertile patients and their partners must agree to use medically
             accepted methods of contraception during therapy and 3 months after the last dose of
             the study drugs.

          -  Female patients of childbearing potential must have a negative pregnancy test at
             screening.

          -  Patient must understand and be willing to give written informed consent prior to any
             study procedures or evaluations and be willing to adhere to all study schedules and
             requirements.

        Exclusion Criteria:

          -  Uncontrolled Intercurrent illness or any history of significant cardiac, renal,
             neurologic, metabolic, pulmonary, gastrointestinal, hematologic abnormality, chronic
             hepatic disease or any other disease which in the judgment of the investigator would
             interfere with the study or confound the results.

          -  Other active cancer disease.

          -  Serum creatinine &gt; 1.5 mg/dL for males and &gt;1.4 mg/dL for females.

          -  Female patient who are breastfeeding or have a positive pregnancy test at screening
             or at any time during the study.

          -  Any acute cardiovascular event during the last 6 months prior to inclusion.

          -  Symptomatic congestive heart failure with ejection fraction &lt; 30%.

          -  Patient has prothrombin time/International Normalization Ration (PT/INR) or partial
             thromboplastin time (PTT) test results &gt; 1.3 UNL.

          -  Hemoglobin ≤  11 g/dL

          -  Platelets &lt; 150,000 per microliter

          -  White blood cell count&lt;3,000 x109/L and/or absolute neutrophils count &lt;1.5 x 109/L

          -  Significant swallowing disorders.

          -  History of small bowel surgery.

          -  Any history of pelvic or abdominal radiation.

          -  Pre-existing mal-absorption syndrome, irritable bowel syndrome or other clinical
             situation which could affect oral absorption.

          -  Mental disorders.

          -  Inability to give written informed consent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lior Heller, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assaf Harofeh Medical Center, Zrifin, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanna Levy, Dr</last_name>
    <phone>+972-52-2824966</phone>
    <email>hanna@oshadi-da.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assaf-Harofeh Medical Center</name>
      <address>
        <city>Zrifin</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanna Levy, Dr.</last_name>
      <phone>+972-52-282-4966</phone>
      <email>hanna@oshadi-da.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 9, 2013</lastchanged_date>
  <firstreceived_date>December 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BCC</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antineoplastic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
